Viratherapeutics GmbH
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Oct 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,963,718 | LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,265,357 | Compositions, Methods and Uses for Treating Solid Tumors Using Lcmv-Gp-Vsv Pseudotype Vectors In force · Low confidence | In force | Low confidence | |
| US 9,650,649 | LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors In force · From the USPTO record | In force | From the USPTO record | |
| US 12,760,322 | Novel Mechanism to Control RNA Virus Replication and Gene Expression In force · High confidence | In force | High confidence | |
| US 12,522,844 | VSV Chimeric Vectors In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 2 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
Every application published under this name has become a patent.